title: Suppression of Acid Sphingomyelinase Protects the Retina from Ischemic Injury.
abstract: Acid sphingomyelinase (ASMase) catalyzes the hydrolysis of sphingomyelin to ceramide and mediates multiple responses involved in inflammatory and apoptotic signaling. However, the role ASMase plays in ischemic retinal injury has not been investigated. The purpose of this study was to investigate how reduced ASMase expression impacts retinal ischemic injury.
  
  
  
  Changes in ceramide levels and ASMase activity were determined by high performance liquid chromatography-tandem mass spectrometry analysis and ASMase activity. Retinal function and morphology were assessed by electroretinography (ERG) and morphometric analyses. Levels of TNF-α were determined by ELISA. Activation of p38 MAP kinase was assessed by Western blot analysis.
  
  
  
  In wild-type mice, ischemia produced a significant increase in retinal ASMase activity and ceramide levels. These increases were associated with functional deficits as measured by ERG analysis and significant structural degeneration in most retinal layers. In ASMase+/- mice, retinal ischemia did not significantly alter ASMase activity, and the rise in ceramide levels were significantly reduced compared to levels in retinas from wild-type mice. In ASMase+/- mice, functional and morphometric analyses of ischemic eyes revealed significantly less retinal degeneration than in injured retinas from wild-type mice. The ischemia-induced increase in retinal TNF-α levels was suppressed by the administration of the ASMase inhibitor desipramine, or by reducing ASMase expression.
  
  
  
  Our results demonstrate that reducing ASMase expression provides partial protection from ischemic injury. Hence, the production of ceramide and subsequent mediators plays a role in the development of ischemic retinal injury. Modulating ASMase may present new opportunities for adjunctive therapies when treating retinal ischemic disorders.
authors: Storm Eye Institute Medical University of South Carolina, Department of Ophthalmology, Charleston, South Carolina, United States.
authors: Jie
authors: J
authors: Fan
authors: Departments of Immunology and Microbiology, Medical University of South Carolina, Charleston, South Carolina, United States.
authors: Bill X
authors: BX
authors: Wu
authors: Storm Eye Institute Medical University of South Carolina, Department of Ophthalmology, Charleston, South Carolina, United States.
authors: Craig E
authors: CE
authors: Crosson
mesh_terms: D000818:Animals; D017209:Apoptosis; D015153:Blotting, Western; D002518:Ceramides / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D003891:Desipramine / Q000494:pharmacology*; D004195:Disease Models, Animal; D004596:Electroretinography; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D015427:Reperfusion Injury / Q000150:complications / Q000378:metabolism / Q000517:prevention & control*; D012160:Retina / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology; D012162:Retinal Degeneration / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D015398:Signal Transduction; D013108:Sphingomyelin Phosphodiesterase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D002518:Ceramides; D004791:Enzyme Inhibitors; D014409:Tumor Necrosis Factor-alpha; D013108:Sphingomyelin Phosphodiesterase; D003891:Desipramine